Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: A three-year prospective study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 57, Issue 9, 2002, Pages 785-790

  Pifferi, M ^a   Baldini, G ^a   Marrazzini, G ^a   Baldini, M ^a   Ragazzo, V ^a   Pietrobelli, A ^b   Boner, A L ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Allergy; Bronchial reactivity; Children; Lung function; Specific immunotherapy

Indexed keywords

ADOLESCENT; ARTICLE; ASTHMA; BRONCHUS REACTIVITY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOTHERAPY; LUNG FUNCTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIZATION; STANDARD; TREATMENT OUTCOME; BREATHING MECHANICS; BRONCHUS HYPERREACTIVITY; DESENSITIZATION; IMMUNOLOGY; INHALATION TEST; PATHOPHYSIOLOGY; SKIN TEST;

ADOLESCENT; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; CHILD; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMAN; MALE; METHACHOLINE CHLORIDE; PROSPECTIVE STUDIES; RESPIRATORY MECHANICS; SKIN TESTS; HUMANS;

DIAGNOSTIC AGENT; HOUSE DUST ALLERGEN; METHACHOLINE CHLORIDE;

EID: 0036724457     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2002.23498.x     Document Type: Article

References (48)

1. The future for immunotherapy
2. Childhood asthma: Application of the international view of management in Australia and New Zealand
3. Position paper: Immunotherapy
4. Position paper on allergen immunotherapy
5. Is allergen immunotherapy effective in asthma?: A meta-analysis of randomized controlled trials
6. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma
7. A double-blind multicentre immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results
8. Efficacy of specific immunotherapy in allergic asthma: Myth or reality?
9. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force
10. Immunotherapy. Position paper
11. Methods of skin testing. Position paper
12. Standardization of spirometry - 1987 Update
13. Guidelines for standardization of bronchial challenges with (nonspecific) bronchoconstricting agents
14. Intrasubject between-day variability of PD20 methacholine assessed by the dosimeter inhalation test
15. Evaluation of non-specific bronchial hyperreactivity in different respiratory diseases
16. Specific immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae results in decreased bronchial hyperreactivity
17. Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of pediatric asthma patients
18. Non-allergic bronchial hyperreactivity in asthmatic children decreases with age and increases with mite immunotherapy
19. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses
20. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus)
21. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma
22. Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronyssinus-sensitive allergic asthma under therapy with allergen-antibody complexes
23. Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from Timothy pollen and a four-Grass pollen mixture respectively
24. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment
25. Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus)
26. Cat- or dog-induced immediate and late asthmatic responses before and after immunotherapy
27. A controlled trial of immunotherapy for asthma in allergic children
28. Do asthmatic children benefit from specific immunotherapy?
29. Specific immunotherapy in rhinitis and asthma
30. Mucosal inflammation in asthma
31. Asthma, from bronchoconstriction to airways inflammation and remodeling
32. Computed tomography of the lungs in asthma: Influence of disease severity and etiology
33. Rate of decline of lung function in subjects with asthma
34. A 10 year follow up of 180 adults with bronchial asthma: Factors important for the decline in lung function
35. Specific immunotherapy in asthma: Is it effective?
36. Immunotherapy and allergic inflammation
37. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitization in children
38. Does allergen immunotherapy alter the natural course of allergic disorders?
39. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study
40. Position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
41. Relations of bronchial responsiveness to allergy skin test reactivity, lung function, respiratory symptoms, and diagnoses in thirteen-year-old New Zealand children
42. Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: A dose-titration study